approval · primary record
RISPERIDONE
4 approval events · latest 2026-04-30
| Agency | FDA |
|---|---|
| Submission type | NDA |
| Latest action | 2026-04-30 |
| Approval events | 4 |
| Brand | PERSERIS KIT |
| Sponsor | INDIVIOR |
| Route | SUBCUTANEOUS |
Approval history
4 actions on record. The drug is the stable record; each action below is an event with its own date, so this URL keeps working as new actions arrive.
| Date | Agency | Type | Brand | Sponsor | Route |
|---|---|---|---|---|---|
| 2026-04-30 | FDA | NDA | PERSERIS KIT | INDIVIOR | SUBCUTANEOUS |
| 2026-01-16 | FDA | NDA | RYKINDO | SHANDONG LUYE | INTRAMUSCULAR |
| 2025-10-10 | FDA | NDA | UZEDY | TEVA | SUBCUTANEOUS |
| 2025-01-22 | FDA | NDA | RISPERDAL | JANSSEN PHARMS | ORAL |
Provenance
- Source: openFDA Drugs@FDA
- Fetched at: 2026-10-30T00:28:01.205Z
- Licence class: public-domain
- Verdict: primary-source
- Entity id: approval:risperidone
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Risperidone · compound